SSTR2 and nasopharyngeal carcinoma: SSTR2 therefore shows potential as a diagnostic NPC biomarker when coupled with appropriate imaging techniques as demonstrated by a recent clinical trial published in 2021 as part of a larger study by Lechner et al., which found a significant correlation of SSTR2 expression with in vivo 68-DOTA-peptide uptake in 12 NPC patients [5].